About Synvista Therapeutics
Synvista Therapeutics is a biopharmaceutical company developing clinical laboratory tests and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a protein-based clinical test to identify patients with Hp2-2 diabetes. This test, or a similar genetic form of the test, may be useful in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.
Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure.
For more information, please visit the Company's Web site at http://www.synvista.com.
Any statements contained in this press release that relate to future
plans, events or performance are forward-looking statements that involve
risks and uncertainties including, but not limited to, the risks associated
with the events described in this press release, future clinical
development of Synvista Therapeutics' diagnostic tests and product
candidates, and other risks identified in Synvista Therapeutics' filings
with the Securities and Exchange Commission. Further information on risks
faced by Synvista are detailed under the caption "Risk Factors" in Synvista
|SOURCE Synvista Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved